Enlicitide: An Oral PCSK9 Inhibitor for LDL-Cholesterol Reduction
Enlicitide (marketed as LIPFENDRA) is an oral macrocyclic peptide PCSK9 inhibitor approved for lowering LDL-cholesterol in adults with hypercholesterolemia who require additional lipid-lowering therapy beyond statins. 1
Mechanism of Action
Enlicitide works by binding to proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from binding to low-density lipoprotein receptors (LDLR) on hepatocytes. By blocking this interaction, enlicitide prevents LDLR degradation, thereby increasing the number of receptors available to clear LDL-cholesterol from the bloodstream. 1
Clinical Efficacy
The drug demonstrates robust LDL-cholesterol lowering:
- Primary efficacy: Reduces LDL-C by approximately 57-65% from baseline at 24 weeks 2
- Comparative superiority: In head-to-head trials, enlicitide achieved -64.6% LDL-C reduction versus -6.3% with bempedoic acid, -27.8% with ezetimibe, and -36.5% with bempedoic acid plus ezetimibe combination (all P<0.001) 3
- Additional lipid effects: Also significantly reduces apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) levels 2
Dosing and Administration
The recommended dose is 20 mg once daily, taken on an empty stomach at least 30 minutes before the first meal of the day. 1 This timing is critical—taking enlicitide 30 minutes after a meal reduces drug exposure by approximately 48-50%. 1
Key administration details:
- Can be taken with black coffee or plain tea without affecting absorption 1
- Steady-state achieved by approximately 7 days 1
- Oral bioavailability is approximately 1%, facilitated by sodium caprate in the formulation 1
- Maximum PCSK9 reduction (>90%) occurs 0.5-1 hour post-dose 1
Patient Population
Enlicitide is indicated for statin-treated adults with:
- LDL-C ≥55 mg/dL with history of major atherosclerotic cardiovascular disease (ASCVD) event, OR
- LDL-C ≥70 mg/dL at intermediate to high risk for first ASCVD event 3, 2
Safety Profile
The drug demonstrates favorable tolerability:
- Adverse events similar to placebo in controlled trials 2
- No clinically significant QTc prolongation at therapeutic doses 1
- Discontinuation rates due to adverse events comparable across treatment groups 3
Important contraindications and precautions:
- Not established in pediatric patients 1
- Should not be used during pregnancy (crosses placenta in animal studies) 1
- Detected in breast milk of lactating rats at low concentrations; breastfeeding decisions require risk-benefit assessment 1
Pharmacokinetics
- Rapid absorption with Tmax of 0.5-1 hour 1
- Effective half-life: approximately 14 hours 1
- Terminal half-life: approximately 244 hours 1
- Primarily eliminated via glomerular filtration (73% urine, 8% feces) 1
- No dose adjustments needed for age, sex, race, ethnicity, or body weight 1
Clinical Context
Enlicitide represents a significant advancement as the first oral PCSK9 inhibitor, addressing a major limitation of injectable biologics (evolocumab, alirocumab). For patients unable to achieve LDL-C goals on statin therapy alone, enlicitide provides a convenient oral alternative with superior efficacy compared to other oral nonstatin options like ezetimibe or bempedoic acid. 3, 4 Cardiovascular outcome trials are currently underway to establish its impact on major adverse cardiovascular events. 4